本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，上海镁信健康科技集团股份有限公司（以下简称"镁信健康"）日前更新招股书， 继续推进港交所主板上市进程，高盛、中金公司和汇丰担任联席保荐人。 根据最新版本的招股书， 镁信健康2025年前十个月的营收同比增长33.85%至18.73亿元，同期的 毛利超6亿元。 2022年至2024年，镁信健康的营收分别为10.69亿元、12.55亿元和20.35亿元， 高于中国医疗健康行业与保险行业的平均增速；毛利分别为3.32亿元、4.61亿元和7.29亿元。 更值得注意的是， 镁信健康的经调整净亏损从2024年前十月的0.87亿元，缩减至2025年同期的 0.55亿元，同比减亏近四成，成为商业模式走向"盈利可持续"的信号之一。 成立于2017年的镁信健康致力于解决患者、保司与药企面临的筹资与支付挑战，助力推动中国医疗 支付体系变革。这里不妨补充一点，近年来，中国医疗支付体系正从加速从"基本医保单极主 导"向"基本医保+商业保险"多元协同转型。 根据弗若斯特沙利文的数据显示，2019至2024年，中国创新药械市场规模由 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引致的 任何損失承擔任何責任。 Shanghai MediTrust Health Technology Group Co., Ltd.* 上海鎂信健康科技集團股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，當中所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據經香港公司註冊處處長登記的本公司 招股章程作出投資決定；招股章程的文本將於發售期內向公眾刊發。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何 ...

Core Insights - The health insurance premium income for life insurance companies reached 578.4 billion yuan, a year-on-year increase of 0.5%, while property insurance companies reported 181.5 billion yuan, a growth of 8.9%, leading to a total health insurance premium income of 759.9 billion yuan, up 2.4% year-on-year [1][2] Group 1: Market Trends - The growth rate of health insurance premiums has slowed to 2.4% in the first eight months of the year, attributed to consumer tendencies to cut non-essential spending, product homogeneity, and competition from public health insurance [2][3] - The disparity in growth rates between life and property insurance companies is notable, with property insurance companies showing a higher growth rate due to their focus on short-term products and innovative offerings [3] Group 2: Long-term Potential - Experts remain optimistic about the long-term growth potential of health insurance, driven by factors such as an aging population and increasing health awareness among residents [3][4] - The integration of commercial health insurance into a multi-payment system is encouraged by policies, providing opportunities for product innovation and industry collaboration [3][4] Group 3: Role of Multi-Payment Platforms - Multi-payment platforms, such as Shanghai Meixin Health Technology Group, are enhancing the efficiency and value of health insurance services through innovative payment models and comprehensive service systems [4][5] - These platforms are crucial in connecting medical, pharmaceutical, and insurance sectors, reflecting the ongoing development of the "medical insurance" ecosystem [4][5] Group 4: Industry Development - The growth of multi-payment platforms supports the healthy development of both the insurance and pharmaceutical industries by filling coverage gaps and improving patient payment capabilities [5][6] - These platforms are becoming essential links in enhancing the accessibility of innovative medical products and improving the overall healthcare experience for patients [6]

Core Insights - The insurance industry is entering an AI era, with 2025 identified as a pivotal year for AI applications in the sector [1][2] - AI technology is transitioning from niche applications to widespread accessibility across the industry, enabling both large and small insurance firms to leverage AI for competitive advantage [2][3] - The focus of AI applications is shifting from efficiency enhancement to value creation, emphasizing customer experience [3][4] Industry Trends - AI applications are now permeating all aspects of insurance operations, including sales, underwriting, claims, and customer service [2][4] - The adoption of large models in the insurance sector is increasing, with a significant rise in organizations currently using or planning to use AI technologies [2][3] - Innovations showcased at industry events highlight the transition from efficiency-driven solutions to those that enhance customer experience [3][4] AI Application Phases - The application of AI in insurance is categorized into several phases: efficiency enhancement, value creation through data analysis, and cautious exploration of deep decision-making [3][5] - Current AI applications are primarily focused on improving operational efficiency, while value creation through customer insights is being actively tested [3][5] Innovations and Solutions - Notable innovations include Ant Group's AI insurance advisor "Ant Xiaobao," which offers product interpretation and claims support, and the "Yima Direct Payment" platform by Meixin Health, which addresses traditional claims challenges [4][5] - These innovations demonstrate how AI can significantly improve operational efficiency and customer experience by streamlining processes [4][5] Balancing Efficiency and Human Touch - The industry is exploring the "AI + human" service model to maintain service warmth while enhancing efficiency [5][6] - Experts emphasize the importance of human involvement in complex scenarios, particularly in health insurance, where nuanced understanding is critical [6][7] - The future of insurance services is expected to balance standardized AI solutions with personalized human interactions to optimize customer experience [6][7] Recommendations for AI Integration - Key recommendations for deepening AI applications in insurance include prioritizing cost reduction and risk management projects, leveraging data value, enhancing talent development, and being aware of potential risks associated with AI [7]

Core Insights - The "2025 Inclusion. Bund Conference" was held in Shanghai, showcasing the "Yima Zhifu" platform by Magnesium Health, a multi-payment platform for healthcare [1] - The "Yima Zhifu" platform offers a one-stop aggregation model, providing convenient and efficient multi-payment solutions for patients [1] Company Overview - Magnesium Health has partnered with over 20,000 medical institutions, covering not only public hospital general departments but also special departments, international departments, and private medical institutions [1] - The platform has achieved comprehensive coverage of general departments in top-tier hospitals nationwide [1] Future Plans - Magnesium Health aims to strengthen collaborations with pharmaceutical companies, medical institutions, and insurance organizations to build a more efficient, convenient, and inclusive healthcare payment ecosystem [1]

Core Insights - The "2025 Inclusion·Bund Conference" was held in Shanghai, showcasing the "One Code Direct Payment" platform by Meixin Health, which aims to address payment pain points in the healthcare sector and enhance patient access to medications [1][2] - The healthcare industry in China is undergoing significant transformation, moving from a single insurance payment model to a diversified payment system that includes medical insurance, commercial insurance, and other innovative methods [1] - Despite the development of a multi-payment system, challenges remain in the practical implementation, particularly in the "last mile" of payment processes, leading to a fragmented payment environment [1] Group 1 - The "One Code Direct Payment" platform allows users to access various payment methods regardless of whether they hold a commercial insurance policy, optimizing payment solutions based on individual patient needs [2] - The platform's one-stop payment solution significantly reduces the time and effort required for patients to process claims, transforming the payment experience from a week-long process to a quick 30-second transaction [2] - Meixin Health positions itself as an ecosystem platform connecting insurance companies, medical institutions, pharmaceutical companies, and patients, leveraging technology to enhance the efficiency and effectiveness of medical payments [2]

Group 1 - The core viewpoint of the article highlights the introduction of several high-value "star drugs" in the commercial health insurance innovative drug directory, which is expected to create new payment channels and benefit a broader patient population [1][2] - The National Healthcare Security Administration (NHSA) has initiated the adjustment of the commercial health insurance innovative drug directory, marking a significant step towards a multi-layered and balanced payment structure in the healthcare industry [1][2] - According to Frost & Sullivan, the share of commercial health insurance payments is projected to reach 16.3% by 2030, more than doubling from 2024, indicating a growing trend in the market [2] Group 2 - The construction of a diversified medical payment system faces challenges, including fragmented reimbursement rules and payment proportions across different payment methods, which complicates the payment process [2][3] - The "Yima Direct Payment" platform by Meixin Health exemplifies how platform companies are effectively addressing these challenges by integrating various payment solutions and streamlining complex claims processes [3] - The importance of ensuring that innovative drugs are accessible post-launch, including prescription transmission and direct payment capabilities, is emphasized as a critical factor for commercial insurance [2][3]

Group 1 - The core viewpoint of the article is that Shanghai Meixin Health Technology Group Co., Ltd. is seeking to go public in Hong Kong, highlighting its position as a leading multi-payment platform in the pharmaceutical industry and its significant revenue growth potential [1][2][3]. Group 2 - Meixin Health's revenue for 2022, 2023, and 2024 is projected to be RMB 1.069 billion, RMB 1.255 billion, and RMB 2.035 billion respectively, indicating a compound annual growth rate of approximately 38% over the three years [1][2]. - The company reported a narrowing net loss of RMB 0.76 billion in 2024, down from RMB 2.88 billion in 2023 and RMB 4.46 billion in 2022, primarily due to substantial investments in infrastructure and technology [2][3]. - As of December 31, 2024, Meixin Health has served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies and more than 90 insurance companies [2][3]. Group 3 - The demand for innovative pharmaceutical payment solutions and health insurance services is growing, with the market for innovative pharmaceutical solutions expected to increase from RMB 521 billion in 2019 to RMB 910 billion in 2024, and projected to reach RMB 2.433 trillion by 2030 [4]. - The commercial health insurance premium in China is anticipated to rise from RMB 2.429 trillion in 2019 to RMB 4.3 trillion in 2024, with a projected compound annual growth rate of 21.0% from 2024 to 2030 [4]. - The company plans to deepen existing partnerships with pharmaceutical companies and insurance providers while actively seeking new collaboration opportunities to enhance its influence in the healthcare ecosystem [4][5]. Group 4 - Specific plans include collaborating with pharmaceutical companies to include more innovative products in insurance offerings, developing customized insurance products with insurance providers to meet diverse patient needs, and leveraging patient insights to design policies that alleviate financial burdens [5][6]. - Meixin Health aims to launch a consumer-centric one-stop service platform called "Yima Zhifu," integrating resources from pharmaceuticals, healthcare, and insurance to provide more payment options and enhance user experience [6].

Core Insights - The launch of the first national "Medical Insurance + Commercial Insurance" clearing and settlement center marks a significant shift in the payment landscape, allowing seamless integration between medical insurance and commercial insurance, reducing the burden on patients [1][2] - The integration of medical insurance and commercial insurance is entering a fast track, with various companies leveraging their strengths to innovate and enhance payment efficiency [2][4] Group 1: Policy and Technological Developments - The National Medical Insurance Administration has expressed a commitment to exploring the collaborative development of basic medical insurance and commercial medical insurance, with the recent establishment of the clearing center being a pilot project aimed at facilitating this integration [2] - Companies like Megxin Health have pioneered concepts such as "commercial insurance identity medical treatment," introducing platforms that allow for direct payment at public hospitals, enhancing user experience by enabling "pay after treatment" [2][4] Group 2: Innovations by Key Players - Alipay has introduced the "Commercial Insurance Code," which utilizes national medical insurance data to streamline the settlement process, significantly reducing the financial burden on patients [3][4] - Ping An Good Doctor has launched "Ping An Medical Payment," a product that leverages medical insurance data to achieve seamless and rapid claims processing, creating a closed-loop payment and service model [3][4] Group 3: Industry Transformation and Future Outlook - The integration of medical insurance and commercial insurance is redefining the concept of "innovative payment," enhancing payment efficiency and improving the quality of life for patients [5][6] - The shift from simple complementarity to a data and service ecosystem is driving competition in the health insurance sector, moving away from price wars to service-oriented competition [6][8] - The anticipated full implementation of the "Medical Insurance + Commercial Insurance" one-stop settlement model is projected to unlock a trillion-level health insurance market, fostering a new ecosystem of medical, insurance, and technology integration [7][8]

Core Viewpoint - Magnesium Health aims to transform China's medical payment system and has become the largest multi-payment platform in the country, with a valuation of 11.6775 billion RMB after the last round of financing before its IPO [1][11]. Group 1: Company Overview - Founded in 2017, Magnesium Health focuses on addressing financing and payment challenges faced by patients, insurers, and pharmaceutical companies [2]. - As of December 31, 2024, Magnesium Health has saved patients approximately 6.7 billion RMB in out-of-pocket expenses through its solutions [2]. - The company has developed two major industry solutions: Smart Drug Solutions and Smart Insurance Solutions, ranking first in China for innovative drug and health insurance solutions [2][4]. Group 2: Market Position and Reach - By the end of 2024, Magnesium Health has served around 1.6 million patients, with a total medical expenditure GPV of 39.7 billion RMB [4]. - The company collaborates with over 90 insurance companies, including the top 20 in China by premium income, and more than 140 pharmaceutical companies, covering 40% of listed Class 1 new drugs in China [4]. Group 3: Financial Performance - Revenue for Magnesium Health from 2022 to 2024 was 1.069 billion RMB, 1.255 billion RMB, and 2.035 billion RMB, respectively, with gross profit margins of 31.1%, 36.8%, and 35.8% [7]. - The adjusted net losses for the same period were 447 million RMB, 290 million RMB, and 80 million RMB, showing a significant narrowing trend in loss rates [8]. Group 4: Industry Growth Potential - The Chinese healthcare market is expected to continue growing, driven by favorable government policies, an aging population, and increasing public health awareness [9]. - The innovative drug and medical device market in China is projected to grow from 92.3 billion RMB in 2019 to 162 billion RMB in 2024, with a compound annual growth rate (CAGR) of 11.9% [9]. Group 5: Future Plans and Use of IPO Proceeds - The net proceeds from the IPO will be used to expand and upgrade services for pharmaceutical companies and insurers, develop the integrated payment platform, and enhance key infrastructure [11].